These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
98 related articles for article (PubMed ID: 4661749)
1. Susceptibility of Runyon Group I Mycobacteria to rifampicin. Saito H; Yamamoto S; Yamura T Hiroshima J Med Sci; 1972 Mar; 21(1):35-40. PubMed ID: 4661749 [No Abstract] [Full Text] [Related]
3. Rifampicin-susceptibility and rifampicin-resistance in mycobacteria. Manten A; van Wijngaarden LJ; van Klingeren B Acta Tuberc Pneumol Belg; 1969; 60(3):329-34. PubMed ID: 4984415 [No Abstract] [Full Text] [Related]
4. The relationship between the in vitro drug susceptibility of opportunist mycobacteria and their in vivo response to treatment. Heginbothom ML Int J Tuberc Lung Dis; 2001 Jun; 5(6):539-45. PubMed ID: 11409581 [TBL] [Abstract][Full Text] [Related]
5. [Rifampicin sensitivity of mycobacteria]. Daddi G; Lucchesi M; Mancini P; Matzeu M; Rossi P Ann Ist Carlo Forlanini; 1969; 29(1):17-28. PubMed ID: 4996680 [No Abstract] [Full Text] [Related]
6. Activity of rifampicin on Mycobacterium ulcerans. Havel A; Pattyn SR Ann Soc Belg Med Trop; 1975; 55(2):105-8. PubMed ID: 1164050 [No Abstract] [Full Text] [Related]
7. Sporotrichoid Mycobacterium marinum infection in diabetes. Chemotherapy with rifampin and ethambutol. Bodaness RS N Y State J Med; 1978 Oct; 78(12):1935-6. PubMed ID: 279836 [No Abstract] [Full Text] [Related]
8. "In vitro" action of rifampicin on typical and atypical mycobacteria. Tanzil HO; Chatim A; Rachim A; Judanarso D Acta Tuberc Pneumol Belg; 1972; 63(1):140-7. PubMed ID: 4631816 [No Abstract] [Full Text] [Related]
9. In vitro susceptibility of atypical mycobacteria to rifampin. Molavi A; Weinstein L Appl Microbiol; 1971 Jul; 22(1):23-5. PubMed ID: 5111305 [TBL] [Abstract][Full Text] [Related]
11. Acquired resistance to rifampicin by Mycobacterium kansasii. Davidson PT; Waggoner R Tubercle; 1976 Dec; 57(4):271-3. PubMed ID: 1014109 [TBL] [Abstract][Full Text] [Related]
12. Sporotrichoid Mycobacterium marinum infection treated with rifampin-ethambutol. Wolinsky E; Gomez F; Zimpfer F Am Rev Respir Dis; 1972 Jun; 105(6):964-7. PubMed ID: 5032717 [No Abstract] [Full Text] [Related]
13. [Number of rifampicin- and ethambutol-resistant variants in strains of atypical mycobacteria pathogenic for man, on Loewenstein-Jensen media]. Le Lirzin M; Boisvert H Ann Inst Pasteur (Paris); 1971 Apr; 120(4):549-59. PubMed ID: 5564197 [No Abstract] [Full Text] [Related]
14. [Sensitivity "in vitro" of human tubercular mycobacteria and atypical mycobacteria to rifampicin]. Mandler F; Garimoldi M G Ital Mal Torace; 1969; ():Suppl 2:7-13. PubMed ID: 4982435 [No Abstract] [Full Text] [Related]
15. Recent clinical advances in knowledge of the nonleprous environmental mycobacteria responsible for cutaneous disease. Wallace RJ Arch Dermatol; 1987 Mar; 123(3):337-9. PubMed ID: 3813601 [No Abstract] [Full Text] [Related]
16. [Sensitivity of atypic mycobacteria to rifampicin and ethambutol]. Makarevitch NM G Ital Chemioter; 1972; 19(2):23-5. PubMed ID: 4666006 [No Abstract] [Full Text] [Related]
18. [Swimming pool granuloma or aquarium disease]. Bourlond A Arch Belg Dermatol; 1973; 29(4):337-8. PubMed ID: 4802336 [No Abstract] [Full Text] [Related]
19. Cutaneous infection due to a Runyon group 3 atypical Mycobacterium. Schmidt JD; Yeager H; Smith EB; Raleigh JW Am Rev Respir Dis; 1972 Sep; 106(3):469-71. PubMed ID: 5080716 [No Abstract] [Full Text] [Related]
20. [Rapid rifampicin susceptibility test by using recombinant mycobacteriophages]. Lü B; Fu Z; Xu S Zhonghua Jie He He Hu Xi Za Zhi; 2000 Aug; 23(8):480-4. PubMed ID: 11778263 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]